To the Editor: Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and peripheral cytopenias, with a risk of progression to acute myeloid leukemia [1]. Although allogeneic hematopoietic stem cell transplantation (HSCT) is the only established curative treatment, relapse after HSCT occurs in ~15–60% of patients [2] and remains a major clinical challenge. A second HSCT is a therapeutic option for these patients.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Hidehiro
Contact Hidehiro, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack